OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours

Nature News · Feb 25, 2026 · Collected from RSS

Full Article

Data availabilityAll generated data and analyses, information and results for this study are included in this Article’s figures, extended data figures and supplementary datasets. Data are available at GitHub (https://github.com/Prenauer/OR7A10_NK_GOF_2025). Raw sequencing data are available for download from the Gene Expression Omnibus with the super-series accession number GSE309802 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309802). Original cell lines are available at the commercial sources listed in the Methods and/or the Reporting Summary. Source data are provided with this paper.Code availability The code used for data analyses and the generation of figures related to this study is available from GitHub (https://github.com/Prenauer/OR7A10_NK_GOF_2025). ReferencesVivier, E., Tomasello, E., Baratin, M., Walzer, T. & Ugolini, S. Functions of natural killer cells. Nat. Immunol. 9, 503–510 (2008).Article PubMed CAS Google Scholar Ben-Shmuel, A., Biber, G. & Barda-Saad, M. Unleashing natural killer cells in the tumor microenvironment—the next generation of immunotherapy?. Front. Immunol. 11, 275 (2020).Article PubMed PubMed Central CAS Google Scholar Guillerey, C., Huntington, N. D. & Smyth, M. J. Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025–1036 (2016).Article PubMed CAS Google Scholar Morvan, M. G. & Lanier, L. L. NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer 16, 7–19 (2016).Article PubMed CAS Google Scholar Raulet, D. H. & Guerra, N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 9, 568–580 (2009).Article PubMed PubMed Central CAS Google Scholar Crinier, A., Narni-Mancinelli, E., Ugolini, S. & Vivier, E. SnapShot: natural killer cells. Cell 180, 1280–1280 (2020).Article PubMed CAS Google Scholar Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9, 495–502 (2008).Article PubMed PubMed Central CAS Google Scholar Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85–100 (2021).Article PubMed Google Scholar Huntington, N. D., Cursons, J. & Rautela, J. The cancer–natural killer cell immunity cycle. Nat. Rev. Cancer 20, 437–454 (2020).Article PubMed CAS Google Scholar Bald, T., Krummel, M. F., Smyth, M. J. & Barry, K. C. The NK cell–cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat. Immunol. 21, 835–847 (2020).Article PubMed PubMed Central CAS Google Scholar Elahi, R., Heidary, A. H., Hadiloo, K. & Esmaeilzadeh, A. Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects. Stem Cell Rev. Rep. 17, 2081–2106 (2021).Article PubMed PubMed Central Google Scholar Marofi, F. et al. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Res. Ther. 12, 200 (2021).Article PubMed PubMed Central CAS Google Scholar Dagher, O. K. & Posey, A. D. Jr. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat. Immunol. 24, 1994–2007 (2023).Article PubMed PubMed Central CAS Google Scholar Hu, W., Wang, G., Huang, D., Sui, M. & Xu, Y. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front. Immunol. 10, 1205 (2019).Article PubMed PubMed Central CAS Google Scholar Albinger, N., Hartmann, J. & Ullrich, E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 28, 513–527 (2021).Article PubMed PubMed Central CAS Google Scholar Wrona, E., Borowiec, M. & Potemski, P. CAR-NK cells in the treatment of solid tumors. Int. J. Mol. Sci. 22, 5899 (2021).Article PubMed PubMed Central CAS Google Scholar Portillo, A. L. et al. Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. iScience 24, 102619 (2021).Article ADS PubMed PubMed Central CAS Google Scholar Shimasaki, N., Jain, A. & Campana, D. NK cells for cancer immunotherapy. Nat. Rev. Drug Discov. 19, 200–218 (2020).Article PubMed CAS Google Scholar Cozar, B. et al. Tumor-infiltrating natural killer cells. Cancer Discov. 11, 34–44 (2021).Article PubMed CAS Google Scholar Christodoulou, I. et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J. Immunother. Cancer 9, e003894 (2021).Article PubMed PubMed Central Google Scholar Vivier, E. et al. Natural killer cell therapies. Nature 626, 727–736 (2024).Article ADS PubMed CAS Google Scholar Bernard, P. L. et al. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity. J. Immunother. Cancer 10, e004244 (2022).Article PubMed PubMed Central Google Scholar Delconte, R. B. et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat. Immunol. 17, 816–824 (2016).Article PubMed CAS Google Scholar Zhu, H. et al. Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. Cell Stem Cell 27, 224–237 (2020).Article PubMed PubMed Central CAS Google Scholar Delconte, R. B. et al. NK cell priming from endogenous homeostatic signals is modulated by CIS. Front. Immunol. 11, 75 (2020).Article PubMed PubMed Central CAS Google Scholar Nakazawa, T. et al. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma. J. Exp. Clin. Cancer Res. 42, 205 (2023).Article PubMed PubMed Central CAS Google Scholar Morimoto, T. et al. CRISPR–Cas9-Mediated TIM3 knockout in human natural killer cells enhances growth inhibitory effects on human glioma cells. Int. J. Mol. Sci. 22, 3489 (2021).Article PubMed PubMed Central CAS Google Scholar Mac Donald, A. et al. KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors. Front. Immunol. 14, 1231916 (2023).Article CAS Google Scholar Qin, Y. et al. Developing enhanced immunotherapy using NKG2A knockout human pluripotent stem cell-derived NK cells. Cell Rep. 43, 114867 (2024).Article PubMed CAS Google Scholar Nakazawa, T. et al. Characterization of HIF-1α knockout primary human natural killer cells including populations in allogeneic glioblastoma. Int. J. Mol. Sci. 25, 5896 (2024).Article PubMed PubMed Central CAS Google Scholar Ni, J. et al. Single-cell RNA sequencing of tumor-infiltrating NK cells reveals that inhibition of transcription factor HIF-1α unleashes NK cell activity. Immunity 52, 1075–1087 (2020).Article PubMed CAS Google Scholar Peng, L. et al. In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nat. Biotechnol. 43, 752–761 (2025).Article PubMed CAS Google Scholar Rafei, H. et al. CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Nature 643, 1076–1086 (2025).Article ADS PubMed PubMed Central Google Scholar Zhang, X. et al. Gene knockout in cellular immunotherapy: application and limitations. Cancer Lett. 540, 215736 (2022).Article PubMed CAS Google Scholar Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR–Cas9 complex. Nature 517, 583–588 (2015).Article ADS PubMed CAS Google Scholar Zhou, X., Renauer, P. A., Zhou, L., Fang, S. Y. & Chen, S. Applications of CRISPR technology in cellular immunotherapy. Immunol. Rev. 320, 199–216 (2023).Article PubMed PubMed Central CAS Google Scholar Chen, H. et al. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target. Theranostics 9, 5246–5260 (2019).Article PubMed PubMed Central CAS Google Scholar Wang, Q. et al. APLN promotes the proliferation, migration, and glycolysis of cervical cancer through the PI3K/AKT/mTOR pathway. Arch. Biochem. Biophys. 755, 109983 (2024).Article PubMed CAS Google Scholar Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548, 537–542 (2017).Article ADS PubMed PubMed Central CAS Google Scholar Karagiota, A., Kanoura, A., Paraskeva, E., Simos, G. & Chachami, G. Pyruvate dehydrogenase phosphatase 1 (PDP1) stimulates HIF activity by supporting histone acetylation under hypoxia. FEBS J. 290, 2165–2179 (2023).Article PubMed CAS Google Scholar Song, Y., Zhang, J., Zhang, L., Zhang, S. & Shen, C. PDP1 promotes cell malignant behavior and is associated with worse clinical features in ovarian cancer patients: evidence from bioinformatics and in vitro level. Comput. Math. Methods Med. 2022, 7397250 (2022).Article PubMed PubMed Central Google Scholar Yuan, M. et al. PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1. Cancer Lett. 597, 217007 (2024).Article PubMed CAS Google Scholar Alshamleh, I. et al. PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia. Leukemia 37, 2367–2382 (2023).Article PubMed PubMed Central CAS Google Scholar Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat. Med. 30, 772–784 (2024).Article PubMed PubMed Central CAS Google Scholar Kremer, V. et al. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. J. Immunother. Cancer 5, 73 (2017).Article PubMed PubMed Central Google Scholar Sun, Y. et al. Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer. Cancer Immunol. Res. 13, 1080–1097 (2025).Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520–531 (2018).Article PubMed CAS Google Scholar Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive l